衰弱与肝硬化疾病进展及死亡风险增加相关
研究纳入北美四中心和印度一中心的822例成人肝硬化患者,用Liver Frailty Index(LFI)基线评估衰弱,按D'Amico分期定义肝硬化进展。在校正年龄、性别和MELD评分后,衰弱(LFI>4.5)较健壮(LFI<3.2)与代偿期肝硬化进展至下一分期或死亡风险增加(HR 2.45;95%CI 1.14-5.29)及非计划住院风险增加(HR 2.32;95%CI 1.13-4.79)相关,失代偿期患者观察到相似HR。
要点
- 衰弱是代偿期和失代偿期肝硬化疾病进展或死亡及非计划住院的独立预测因素。
- 代偿期肝硬化中,衰弱较健壮者进展至下一分期或死亡风险HR为2.45(95%CI 1.14-5.29)。
- 代偿期肝硬化中,衰弱较健壮者非计划住院风险HR为2.32(95%CI 1.13-4.79)。
核心结论
- 衰弱是代偿期和失代偿期肝硬化患者肝硬化进展或死亡以及非计划住院的独立预测因素。
研究设计与样本
- 研究纳入北美四个中心和印度一个中心的822例成人肝硬化患者,基线用Liver Frailty Index(LFI)评估衰弱并分为健壮(LFI<3.2)、前衰弱(LFI 3.2-4.5)和衰弱(LFI>4.5)。
- 肝硬化进展用D'Amico分类定义为临床分期从基线增加(范围1至5),采用多变量回归模型评估进展、死亡和住院相关因素,并将移植作为竞争风险。
- 患者平均Model for End-Stage Liver Disease(MELD)评分为15.5±6.0。
主要发现
- 在代偿期肝硬化患者中,校正年龄、性别和MELD评分后,衰弱较健壮与进展至下一肝硬化分期或死亡风险增加相关(HR 2.45;95%CI 1.14-5.29)。
- 在代偿期肝硬化患者中,校正年龄、性别和MELD评分后,衰弱较健壮与非计划住院风险增加相关(HR 2.32;95%CI 1.13-4.79)。
- 在失代偿期肝硬化患者中观察到与代偿期患者相似的HR。
临床怎么用
- 可将LFI用于肝硬化患者衰弱评估,以识别疾病进展、死亡和非计划住院风险较高的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The Liver Frailty Index (LFI) is a well-studied tool that evaluates frailty in patients with cirrhosis. Consisting of grip strength, chair stands, and balance testing, the LFI has been associated with increased mortality in patients awaiting liver transplant. We aimed to extend our understanding of frailty in cirrhosis by exploring the relationship between the LFI and the risk of (1) cirrhosis progression, (2) mortality, and (3) unplanned hospitalizations, in both compensated and decompensated disease. APPROACH AND RESULTS: Adult patients with cirrhosis from four centers in North America and one in India were included. Frailty was measured at baseline using the LFI and categorized as robust (LFI < 3.2), prefrail (LFI 3.2-4.5), and frail (LFI > 4.5). Progression of cirrhosis was defined by an increase in clinical stage, ranging from 1 to 5, from baseline using the D'Amico classification. Factors associated with progression, mortality, and hospitalizations were evaluated using multivariate regression models, with transplant as a competing risk. In total, 822 patients with cirrhosis were included. Average Model for End-Stage Liver Disease (MELD) score was 15.5 ± 6.0. In patients with compensated cirrhosis, being frail versus robust was associated with increased risk of progression to the next cirrhosis stage or to death (HR, 2.45; 95% CI, 1.14-5.29) and with an increased risk of unplanned hospitalizations (2.32; 95% CI, 1.13-4.79), after adjusting for age, sex, and MELD score. Similar HRs were observed in patients with decompensated cirrhosis. CONCLUSIONS: Frailty was an independent predictor of cirrhosis progression or death and unplanned hospitalization across patients with compensated and decompensated cirrhosis. Future studies are needed to evaluate the possibility of slowing cirrhosis disease progression by reversing or preventing frailty.
引用
- Wang S, Whitlock R, Xu C, et al. Frailty is associated with increased risk of cirrhosis disease progression and death. Hepatology. 2021. PMID: 34528267. doi:10.1002/hep.32157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。